Aug. 12 at 11:27 PM
$SLS Now that Cash Concerns are Off the table - these are Numbers Institutional Funds and Big Pharma are Looking at:
CCo Published Pricing Comps STARTING at
$260K Per Patient, Per Year - Average 24 Months Per Patient
75,000 AML Patients CURRENTLY in AML CR1 or CR2 who will Immediately benefit from Gps Immunotherapy Right out of the Gate
10,000 AML CR2 Patients Each Year * average 2 Years Per Patient - based on 24 Month MEDIAN OS
$5.6B TAM
25,000 AML CR1 Patients Each Year - with Ad Infinitum Dosing, the CR1 Total Addressable Market is Greater than
$10B / year
Add in GPS immunotherapy for additional Patient Settings: GPS + Keytruda
$MRK achieved BETTER Phase 2 MOS Results than Elehare
$IMGN which was bought for
$10.1B by
$ABBV
SLS009 also has proven it will be FDA Approved -
$FTSV 's Magrolimab was bought for
$4.9B based on Lesser P1/2 Data than what SLS009 Just Published in the same AML-MRC Setting.
